Brain cancer Patients' hidden struggle: new study tracks suicide risk
NCT ID NCT07409584
First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 2 times
Summary
This study tracks mental health and suicide risk in 176 adults with glioblastoma, a serious brain cancer. Participants fill out questionnaires about depression, anxiety, quality of life, and suicidal thoughts. The goal is to understand what factors increase suicide risk in these patients, so doctors can offer better support.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors better identify glioblastoma patients at risk of suicide and improve mental health support.
- What could go wrong
- This is an observational study, not a treatment trial. It only measures symptoms and cannot prove what causes them or how to prevent them.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 180 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2026
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
glioblastoma patients
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Newly diagnosed glioblastoma, IDH wild-type (CNS WHO classification of 2021) after finishing radiotherapy (before first recurrence) * Age ≥ 18 years Exclusion Criteria: * Participants with clinically significant aphasia or language barrier as assessed by the investigator * History of other malignant tumors * Known tumor predisposition syndrome (e.g., Li-Fraumeni syndrome, Cowden syndrome, etc.) * Recurrent glioblastoma
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Glioblastoma (GBM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
6 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Charite
RECRUITINGBerlin, Germany
-
University Hospital Essen
RECRUITINGEssen, 45147, Germany
-
University Hospital Knappschaftskrankenhaus Bochum
NOT_YET_RECRUITINGBochum, Germany
-
University hospital Hamburg Eppendorf
RECRUITINGHamburg, Germany
-
University hospital Heidelberg
RECRUITINGHeidelberg, Germany
-
University hospital Muenster
RECRUITINGMünster, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer reveal hidden tumors?
- MRI maps Low-Oxygen tumor zones to sharpen radiation strike
- Can a Custom-Made vaccine train the immune system to fight brain cancer?
- Can a virus injected into brain tumors fight recurrence?
- Can adding lenvatinib to standard care outsmart a tough brain cancer?
- Can a pill reach the brain and fight tumors?